Australian radiopharma developer Telix Pharmaceuticals has filed for a secondary listing, with proposals for an initial public offering in the USA. 20 May 2024
The US Food and Drug Administration (FDA) announced the final withdrawal of the approval of BridgeBio Pharma Truseltiq (infigratinib) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. 20 May 2024
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership 20 May 2024
Cambridge, USA-based generative protein design pioneer Nabla Bio has announced the closure of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors. 20 May 2024
Precision oncology company Erasca, which is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, opened trading 8% higher Friday. 17 May 2024
Cincinnati, USA-based CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension. 16 May 2024
Blackstone has announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug developer on immunology and inflammation. 16 May 2024
USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics has secured $125 million in financing, with the first tranche of $25 million available upon closing. 16 May 2024
May 15, 2024
Texas, USA-based drugmaker Lexicon Pharmaceuticals saw its shares edge up 2.7% to by close of trading yesterday and a further 2% to $1.96 pre-market as its announced new research results on its heart failure drug. 15 May 2024
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the supplemental Biologics License Application (sBLA) for Heplisav-B vaccine, said US immunotherapy specialist Dynavax Technologies. 15 May 2024
Precision oncology platform company Tavros Therapeutics has achieved two milestone payments in its collaboration with the Bayer subsidiary Vividion Therapeutics. 14 May 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now only weeks away, more drugmakers and research groups are lifting the lid on data they intend to present at the event. 14 May 2024
Chinese biopharma company Everest Medicines announced that Nefecon, a delayed release capsule of budesonide, has been successfully launched in China with the first prescription issued. 14 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financing is dwarfed only by Altos Lab’s $3 billion, amassed back in 2021. 14 May 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024